Scynexis (SCYX) Current Assets (2013 - 2026)
Scynexis' (SCYX) quarterly Current Assets came in at $56.2 million in Q2 2026, little changed on a YoY basis from $56.5 million in Q2 2025, and down 10.3% quarter-over-quarter from $62.7 million in Q1 2026.
Analysis
Scynexis (SCYX) Current Assets (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Current Assets for 14 consecutive years, with $56.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Assets changed 0.46% year-over-year to $56.2 million; the trailing twelve-month figure through Jun 2026 stood at $56.2 million (changed 0.46% YoY), and the FY2025 full-year result was $40.4 million, down 44.07% from the prior year.
- Current Assets slipped to $56.2 million in Q2 2026 per SCYX's latest filing, from $62.7 million in the prior quarter.
- Across five years, Current Assets topped out at $145.5 million in Q2 2023 and bottomed at $40.4 million in Q4 2025.
- Historically, Current Assets has averaged $84.0 million across 5 years, with a median of $79.8 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Current Assets surged 70.12% in 2024, then slumped 48.64% in 2025.
- Over 5 years, Current Assets stood at $79.1 million in 2022, then gained by 29.16% to $102.1 million in 2023, then slipped by 29.31% to $72.2 million in 2024, then plunged by 44.07% to $40.4 million in 2025, then soared by 39.29% to $56.2 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $56.2 million, $62.7 million, and $40.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.74 Bn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 56.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.24 Mn |
| Mar 31, 2026 | 62.69 Mn |
| Dec 31, 2025 | 40.37 Mn |
| Sep 30, 2025 | 48.69 Mn |
| Jun 30, 2025 | 56.50 Mn |
| Mar 31, 2025 | 52.22 Mn |
| Dec 31, 2024 | 72.18 Mn |
| Sep 30, 2024 | 80.46 Mn |
| Jun 30, 2024 | 94.58 Mn |
| Mar 31, 2024 | 101.67 Mn |
| Dec 31, 2023 | 102.12 Mn |
| Sep 30, 2023 | 128.64 Mn |
| Jun 30, 2023 | 145.53 Mn |
| Mar 31, 2023 | 59.77 Mn |
| Dec 31, 2022 | 79.06 Mn |
| Sep 30, 2022 | 103.57 Mn |
| Jun 30, 2022 | 125.68 Mn |
| Mar 31, 2022 | 101.91 Mn |
| Dec 31, 2021 | 109.38 Mn |
| Sep 30, 2021 | 103.93 Mn |